Home  /  Resource Library  /  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Results of a phase I study investigating CAR T therapy Lisocabtagene maraleucel for treatment of relapsed large B-cell lymphomas.